Adaptive Biotechnologies Corporation
ADPT
$7.41
-$0.53-6.68%
| Weiss Ratings | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.47 | |||
| Price History | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -12.00% | |||
| 30-Day Total Return | -11.04% | |||
| 60-Day Total Return | 5.11% | |||
| 90-Day Total Return | 67.65% | |||
| Year to Date Total Return | 19.71% | |||
| 1-Year Total Return | 176.49% | |||
| 2-Year Total Return | -14.93% | |||
| 3-Year Total Return | -49.07% | |||
| 5-Year Total Return | -71.19% | |||
| 52-Week High % Change | -11.88% | |||
| 52-Week Low % Change | 248.25% | |||
| Price | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.01 | |||
| 52-Week Low Price | $2.28 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Mar 24, 2025 | |||
| Valuation | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.18B | |||
| Enterprise Value | 1.15B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.09 | |||
| Earnings Per Share Growth | -30.45% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.55 | |||
| Price/Book (Q) | 5.79 | |||
| Enterprise Value/Revenue (TTM) | 6.41 | |||
| Price | $7.41 | |||
| Enterprise Value/EBITDA (TTM) | -8.42 | |||
| Enterprise Value/EBIT | -7.38 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 147.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 206 659 0067 | |||
| Address | 1165 Eastlake Avenue East Seattle, WA 98109 | |||
| Website | www.adaptivebiotech.com | |||
| Country | United States | |||
| Year Founded | 2009 | |||
| Profitability | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -86.80% | |||
| Profit Margin | -89.12% | |||
| Management Effectiveness | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -16.17% | |||
| Return on Equity | -- | |||
| Income Statement | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 178.96M | |||
| Total Revenue (TTM) | 178.96M | |||
| Revenue Per Share | $1.21 | |||
| Gross Profit (TTM) | 110.98M | |||
| EBITDA (TTM) | -136.09M | |||
| EBIT (TTM) | -155.34M | |||
| Net Income (TTM) | -159.49M | |||
| Net Income Avl. to Common (TTM) | -159.49M | |||
| Total Revenue Growth (Q YOY) | 3.66% | |||
| Earnings Growth (Q YOY) | 51.46% | |||
| EPS Diluted (TTM) | -1.09 | |||
| EPS Diluted Growth (Q YOY) | 52.40% | |||
| Balance Sheet | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 222.29M | |||
| Cash Per Share (Q) | $1.51 | |||
| Total Current Assets (Q) | 283.75M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 202.49M | |||
| Current Ratio (Q) | 2.894 | |||
| Book Value Per Share (Q) | $1.37 | |||
| Total Assets (Q) | 539.38M | |||
| Total Current Liabilities (Q) | 98.05M | |||
| Total Debt (Q) | 222.67M | |||
| Total Liabilities (Q) | 336.89M | |||
| Total Common Equity (Q) | 202.71M | |||
| Cash Flow | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 77.79M | |||
| Cash from Financing (TTM) | 241.00K | |||
| Net Change in Cash (TTM) | -17.18M | |||
| Levered Free Cash Flow (TTM) | -24.48M | |||
| Cash from Operations (TTM) | -95.21M | |||
